[07-Jan-2025 01:03:38 UTC] PHP Warning: Use of undefined constant ABSPATH - assumed 'ABSPATH' (this will throw an Error in a future version of PHP) in /home/drkelleyenzymes/public_html/wp-content/themes/thrive-theme/thrive-dashboard/inc/app-notification/classes/DbMigration.php on line 2 [07-Jan-2025 01:03:38 UTC] PHP Warning: require_once(ABSPATHwp-admin/includes/upgrade.php): failed to open stream: No such file or directory in /home/drkelleyenzymes/public_html/wp-content/themes/thrive-theme/thrive-dashboard/inc/app-notification/classes/DbMigration.php on line 2 [07-Jan-2025 01:03:38 UTC] PHP Fatal error: require_once(): Failed opening required 'ABSPATHwp-admin/includes/upgrade.php' (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/drkelleyenzymes/public_html/wp-content/themes/thrive-theme/thrive-dashboard/inc/app-notification/classes/DbMigration.php on line 2 {"id":4507,"date":"2017-03-22T19:57:07","date_gmt":"2017-03-23T02:57:07","guid":{"rendered":"https:\/\/www.drkelleyenzymes.com\/?p=4507"},"modified":"2017-03-22T19:57:07","modified_gmt":"2017-03-23T02:57:07","slug":"pristiq-antidepressant-drug","status":"publish","type":"post","link":"https:\/\/www.drkelleyenzymes.com\/pristiq-antidepressant-drug\/","title":{"rendered":"Pristiq Antidepressant Drug"},"content":{"rendered":"
\n

5 WARNINGS AND PRECAUTIONS<\/h1>\n
<\/a><\/a><\/p>\n

5.1 Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults<\/h2>\n

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and\/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.<\/p>\n

The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.<\/p>\n

<\/a><\/p>\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n
Table 1<\/caption>\n
Age Range<\/th>\nDrug-Placebo Difference in Number of Cases of Suicidality per 1,000 Patients Treated<\/th>\n<\/tr>\n<\/thead>\n
<\/td>\nIncreases Compared to Placebo<\/td>\n<\/tr>\n
<18<\/td>\n14 additional cases<\/td>\n<\/tr>\n
18 to 24<\/td>\n5 additional cases<\/td>\n<\/tr>\n
<\/td>\nDecreases Compared to Placebo<\/td>\n<\/tr>\n
25 to 64<\/td>\n1 fewer case<\/td>\n<\/tr>\n
?65<\/td>\n6 fewer cases<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide.<\/p>\n

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression.<\/p>\n

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.<\/span><\/p>\n

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and\/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.<\/p>\n

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.<\/p>\n

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Dosage and Administration (2.4)<\/a> and Warnings and Precautions (5.7)<\/a> for a description of the risks of discontinuation of PRISTIQ]<\/span>.<\/p>\n

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers<\/span>.<\/p>\n

Prescriptions for PRISTIQ should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.<\/p>\n

<\/a><\/p>\n

Screening patients for bipolar disorder<\/span><\/p>\n

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed\/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that PRISTIQ is not approved for use in treating bipolar depression.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/a><\/p>\n

5.2 Serotonin Syndrome<\/h2>\n

The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including PRISTIQ, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).<\/span><\/p>\n

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and\/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.<\/p>\n

The concomitant use of PRISTIQ with MAOIs intended to treat psychiatric disorders is contraindicated. PRISTIQ should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg\/kg to 8 mg\/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking PRISTIQ. PRISTIQ should be discontinued before initiating treatment with the MAOI [see Contraindications (4.2)<\/span> and Dosage and Administration (2.6)<\/a>]<\/span>.<\/p>\n

If concomitant use of PRISTIQ with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.<\/p>\n

Treatment with PRISTIQ and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.3 Elevated Blood Pressure<\/h2>\n

Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see Adverse Reactions (6.1)<\/a>]<\/span>. Pre-existing hypertension should be controlled before initiating treatment with PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with PRISTIQ.<\/p>\n

Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving PRISTIQ, either dose reduction or discontinuation should be considered [see Adverse Reactions (6.1)<\/a>]<\/span>.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.4 Abnormal Bleeding<\/h2>\n

SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of PRISTIQ and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.5 Angle Closure Glaucoma<\/h2>\n

Angle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including Pristiq may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.6 Activation of Mania\/Hypomania<\/h2>\n

During all MDD phase 2 and phase 3 studies, mania was reported for approximately 0.02% of patients treated with PRISTIQ. Activation of mania\/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.7 Discontinuation Syndrome<\/h2>\n

Discontinuation symptoms have been systematically and prospectively evaluated in patients treated with PRISTIQ during clinical studies in Major Depressive Disorder. Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy.<\/p>\n

During marketing of SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.<\/p>\n

Patients should be monitored for these symptoms when discontinuing treatment with PRISTIQ. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see Dosage and Administration (2.4)<\/a> and Adverse Reactions (6.1)<\/a>]<\/span>.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.8 Seizure<\/h2>\n

Cases of seizure have been reported in pre-marketing clinical studies with PRISTIQ. PRISTIQ has not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from pre-marketing clinical studies. PRISTIQ should be prescribed with caution in patients with a seizure disorder.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.9 Hyponatremia<\/h2>\n

Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol\/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5)<\/a> and Clinical Pharmacology (12.6)]<\/span>. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.<\/p>\n

Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and\/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.<\/p>\n<\/div>\n

<\/a><\/a><\/p>\n

5.10 Interstitial Lung Disease and Eosinophilic Pneumonia<\/h2>\n

Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with PRISTIQ who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of PRISTIQ should be considered.<\/p>\n<\/div>\n<\/div>\n

<\/a><\/a><\/p>\n

6 ADVERSE REACTIONS<\/h1>\n

The following adverse reactions are discussed in greater detail in other sections of the label.<\/p>\n